07:58 AM EDT, 05/27/2025 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) shares fell 64% pre-bell Tuesday after the company said a patient participating in a phase 2 trial of its investigational therapy for Danon disease, a type of genetic disorder, experienced an unexpected "serious" adverse event.

Prothena ( PRTA ) shares were down 27% after the company said late Friday that it will stop the development of birtamimab after a phase 3 trial for amyloid light chain amyloidosis failed to reach its primary endpoint.

PDD (PDD) shares retreated 17% after the company reported lower Q1 adjusted earnings.

Wellgistics Health ( WGRX ) stock was down 12%, adding to Friday's losses.